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ABSTRACT
Introduction Atrial fibrillation (AF) is associated with 
significantly impaired quality- of- life. Iron deficiency (ID) 
is prevalent in patients with AF. Correction of ID in other 
patient populations with intravenous iron supplementation 
has been shown to be a safe, convenient and effective way 
of improving exercise tolerance, fatigue and quality- of- life. 
The IRON- AF (Effect of Iron Repletion in Atrial Fibrillation) 
study is designed to assess the effect of iron repletion with 
intravenous ferric carboxymaltose in patients with AF and 
ID.
Methods and analysis The IRON- AF study is a double- 
blind, randomised controlled trial that will recruit at least 
84 patients with AF and ID. Patients will be randomised 
to receive infusions of either ferric carboxymaltose 
or placebo, given in repletion and then maintenance 
doses. The study will have follow- up visits at weeks 
4, 8 and 12. The primary endpoint is change in peak 
oxygen uptake from baseline to week 12, as measured 
by cardiopulmonary exercise testing (CPET) on a cycle 
ergometer. Secondary endpoints include changes in 
quality- of- life and AF disease burden scores, blood 
parameters, other CPET parameters, transthoracic 
echocardiogram parameters, 6- minute walk test distance, 
7- day Holter/Event monitor burden of AF, health resource 
utilisation and mortality.
Ethics and dissemination The study protocol has been 
approved by the Central Adelaide Local Health Network 
Human Research Ethics Committee, Australia. The results 
of this study will be disseminated through publications in 
peer- reviewed journals and conference presentations.
Trial registration number Australian New Zealand 
Clinical Trials Registry (ACTRN12620000285954).
INTRODUCTION
Atrial fibrillation (AF) is the most common 
sustained arrhythmia faced in clinical prac-
tice, and is independently associated with 
an increased risk of stroke, heart failure and 
death.1 Hospitalisations for AF have been 
exponentially increasing, and the disease 
represents a growing burden on the health-
care systems worldwide.2–4 This increasing 
trend is likely multifactorial, fuelled by the 
growing burden of cardiometabolic risk 
factors such as obesity, an ageing population, 
Strengths and limitations of this study
 ► This double- blind, randomised, placebo- controlled 
trial will provide clinically relevant evidence on the 
effect of iron repletion with intravenous ferric car-
boxymaltose on exercise tolerance in patients with 
atrial fibrillation (AF) and iron deficiency, as mea-
sured by cardiopulmonary exercise testing.
 ► Other clinically important endpoints will be as-
sessed, including quality- of- life and disease bur-
den assessed by questionnaires, changes to blood 
and echocardiogram parameters, 6- minute walk 
test distance and AF burden on 7- day Holter/Event 
monitoring.
 ► Iron deficiency will be defined according to the 
definition used in the clinical trials of iron repletion 
in heart failure patients: serum ferritin <100 µL or 
serum ferritin <300 µL with transferrin saturation 
<20%.
 ► The IRON- AF trial will provide the first assessment 
on the potential efficacy of iron repletion in patients 
with AF. Though objective exercise testing will be 
performed, study findings pertaining to improve-
ments in symptoms will be limited by self- reported 
questionnaires; demonstration of a benefit in terms 
of hospitalisations would require a larger sample 
size and longer duration of follow- up.
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as well as recurrent admissions due to medical complica-
tions and recurring symptoms.5
Individuals with AF have an impaired functional status 
and quality- of- life (QoL) that is widely affected across 
domains of physical and social functioning, mental and 
general health.6 7 One of the cardinal symptoms of AF is 
reduced exercise capacity, and this occurs regardless of 
the presence of heart failure.8–12 Other prominent symp-
toms such as dyspnoea and fatigue are also associated with 
a reduction in functional status, and a greater burden of 
AF symptoms is negatively correlated with QoL.13 Despite 
the symptomatic benefits that cardioversion and catheter 
ablation may provide,14 15 recurrences are common. There 
is thus a need for novel treatments to improve the symp-
tomatology of patients with AF, beyond the pillars of rate 
control, rhythm control and risk factor management.16 
Treatments targeting exercise intolerance in particular as 
a therapeutic goal may bring improvements to symptoms 
and QoL,17 and may also encourage greater engagement 
with risk factor management. Epidemiological studies 
also have shown poor cardiorespiratory fitness in patients 
with AF to be a predictor of arrhythmia recurrence,18 19 as 
well as all- cause and cardiovascular mortality.20
Iron plays an important role in cardiorespiratory 
fitness and is essential in the uptake, transport, storage 
and utilisation of oxygen through haem, and in various 
iron- dependent oxidative enzymes and processes such as 
neurotransmitter synthesis, protein synthesis and organ-
ogenesis.21 Iron deficiency (ID) that leads to anaemia 
impairs physical work performance most evidently through 
a reduction in oxygen transport, the most important 
determinant of maximal oxygen consumption (VO2max). 
However, ID even in the absence of anaemia may atten-
uate exercise performance, owing to the reduced activity 
of iron- dependent oxidative enzymes that are particularly 
important in the ability to maintain prolonged submax-
imal exercise.22 23 In observational studies of heart failure 
patients, ID independent of the presence of anaemia is 
associated with reduced VO2peak and high minute ventila-
tion/carbon dioxide production (VE/VCO2) slope.
24 25 ID 
has also been shown to be a stronger predictor of poorer 
QoL in these patients than the presence of anaemia.26 27
ID that leads to anaemia warrants treatment with iron 
supplementation, but the role of iron supplementation 
in non- anaemic ID is less established. In the younger and 
healthy population, improvements in fatigue but not exer-
cise tolerance may be seen.28 In patients with heart failure 
with reduced ejection fraction (HFrEF) and concurrent 
ID, randomised controlled trials of intravenous iron reple-
tion have shown significant improvements in symptoms, 
exercise tolerance, QoL and heart failure hospitalisations, 
regardless of the presence of anaemia.29–31 Importantly, 
these trials recruited participants using a definition of 
functional ID, reflecting a state of maldistribution of iron 
in the body seen in chronic inflammatory states. Ferritin 
is non- specifically elevated as an acute- phase reactant 
with inflammation due to increased hepcidin produc-
tion and subsequent inhibition of ferroportin, leading to 
impaired absorption and utilisation of iron. To account 
for this, functional ID has previously been defined as a 
serum ferritin <100 µL, or serum ferritin <300 µL with 
transferrin saturation (Tsat) <20%. Using this definition, 
a recent retrospective study examining patients with non- 
valvular AF without heart failure demonstrated that ID 
was present in 48% of patients.32
Further investigation into haematinic deficiencies in 
AF is likely worthwhile for two reasons: first, the patho-
physiology of AF and HF are closely interlinked, and 
inflammation has been implicated in both pathological 
processes.33 Second, anaemia is a common comorbidity 
in individuals with AF, present in approximately 16% of 
patients.34 Potential explanations for both anaemia and 
ID in these patients include chronic inflammation and 
an increased risk of clinically evident or occult bleeding 
with the use of oral anticoagulants. Of note, observational 
data demonstrate that anaemia is independently associ-
ated with increased mortality, stroke/systemic thrombo-
embolism and bleeding in patients with AF.34
Iron supplementation in patients with AF and comorbid 
ID has not been studied previously but may be a simple 
and convenient way to potentially provide symptomatic 
relief from fatigue and exercise intolerance. Thus, the 
IRON- AF (Effect of Iron Repletion in Atrial Fibrillation) 
trial was designed to assess the effect of the supplemen-
tation of iron with intravenous ferric carboxymaltose 
(FCM) on exercise tolerance, fatigue, QoL and other 
parameters in patients with AF and ID.
METHODS AND ANALYSIS
The IRON- AF study is an investigator- initiated, double- 
blind, randomised, placebo- controlled trial. The overall 
study design is outlined in figure 1, and the study inclu-
sion and exclusion criteria are listed in box 1. The key 
inclusion criteria are (1) paroxysmal or persistent AF; (2) 
serum ferritin <100 µL, or serum ferritin <300 µL with 
Tsat <20%; and (3) haemoglobin (Hb) <150 g/L.
Baseline testing
After obtaining written informed consent and 
confirming eligibility, patients will have baseline assess-
ments performed, including medical history (including 
comorbidities and medications) and anthropomorphic 
measures, health questionnaires (including a fatigue 
score, the Atrial Fibrillation Severity Scale [AFSS], the 
36- Item Short Form Survey [SF-36] and the Atrial Fibril-
lation Effect on Quality- of- Life Questionnaire [AFEQT]), 
resting transthoracic echocardiogram (TTE), 6- minute 
walk test (6MWT), cardiopulmonary exercise testing 
(CPET) and a 7 day Holter/Event monitor. Participants 
will undergo randomisation following completion of all 
baseline tests.
Study randomisation
Participants will be randomised using a computer- 
generated randomisation schedule in a 1:1 ratio to either 
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active treatment or placebo using permutated blocks of 
random sizes. We anticipate that a number of recruited 
participants will be concurrently involved in our AF risk 
factor management clinics involving weight and physical 
activity counselling,35 and so randomisation will be strat-
ified according to baseline participation in these clinics.
Study drug and blinding
The active treatment is FCM (Ferinject, Vifor Pharma, 
Australia), to be delivered intravenously as an undiluted 
bolus dose, over 15 min for doses ≥500 mg or at a rate 
of 100 mg/min for doses <500 mg. The placebo is 0.9% 
sodium chloride, to be delivered intravenously at the 
equivalent rate. FCM is a dark brown solution and there-
fore easily distinguishable from placebo. Hence, to main-
tain subject blinding, both the study drug and placebo 
will be delivered with the participant’s arm behind an 
opaque curtain.
For subjects in the active treatment group, the dose of 
FCM for repletion will be calculated using the Ganzoni 
formula shown in figure 2. During week 0, subjects in 
the active treatment group will receive FCM, up to a 
maximum dose of 1000 mg. Should the dose for repletion 
not be completely delivered then, participants will return 
during week 1 to receive the remainder of the dose.
At the start of weeks 4 and 8, subjects will have iron 
studies performed. The results of these studies will be 
reviewed by an unblinded study coordinator not involved 
in assessments of efficacy or safety. Subjects will then 
return to the study centre at the end of weeks 4 and 8 
and receive either a maintenance dose of 200 mg FCM 
or placebo, according to treatment group. In the active 
treatment group, in cases of elevated levels of Hb >160 
g/L, ferritin >800 µg/L or ferritin >500 µg/L when Tsat 
>50%, placebo will be given instead of FCM.
Study end point and assessments
The primary, secondary and safety endpoints are listed in 
box 2. Clinical assessments for efficacy and safety will be 
completed at follow- up visits in week 4, week 8, and the 
final visit in week 12. All study coordinators involved in 
performing clinical assessments will be blinded to partic-
ipant’s group allocation. The primary efficacy assessment 
for VO2peak will occur in week 12 derived by CPET.
CPET will be conducted using an electromagnetically 
controlled cycle ergometer (Corvial, Lode, The Nether-
lands) with a 1 min ramp protocol to volitional exhaus-
tion. Twelve- lead ECG (Vyntus ECG, Vyaire, USA) will be 
monitored to record heart rate and rhythm throughout 
rest, exercise and recovery. Pulmonary gas exchange 
will be recorded continuously through a metabolic 
cart (Vyntus CPX, Vyaire, USA). Resting measures will 
be obtained during a minimum of 2 min seated rest. A 
minimum of 2 min recovery will be commenced after 
participants attained peak exercise. The anaerobic 
threshold will be determined using the V- slope method. 
VO2peak will be taken as the highest 20 second averaged 
sample of VO2 during peak exercise, and predicted values 
of VO2peak will be obtained using the Wasserman and 
Hansen equations.36 VE/VCO2 will be calculated by using 
a linear regression slope of minute ventilation and CO2 
output between rest and peak exercise.
Resting transthoracic echocardiography (Vivid 7, GE 
Healthcare, Norway) will be performed at baseline and 
week 12. Transthoracic images will be obtained in the 
apical four- chamber, three- chamber and two- chamber 
views, and parasternal long and short axis views. Echo-
cardiographic variables, including systolic and diastolic 
function, atrial volumes and global longitudinal strain, 
will be collected and analysed by a sonographer, and 
subsequently analysed by a cardiologist blinded to the 
randomisation.
Blood parameters collected will include a complete 
blood count, iron studies (including serum iron, ferritin, 
transferrin and transferrin saturation), electrolytes, urea, 
creatinine, liver function tests, C- reactive protein, eryth-
rocyte sedimentation rate and NT- proB- type natriuretic 
peptide. Values will be obtained at baseline, weeks 4, 8 
and 12, with venesection performed prior to infusions 
and/or assessments. If a significant reduction in haemo-
globin is detected during the course of monitoring, the 
participant’s treating physicians will be informed and 
a decision to withdraw from the study will be made in 
conjunction with the participant’s wishes.
Validated generic and disease- specific QoL question-
naires, including the SF-36 and AFEQT, as well as a vali-
dated disease- specific symptom questionnaire, the AFSS, 
will be used to characterise changes to patient well- being 
Figure 1 Schema of the IRON- AF trial. 6MWT, 6- minute walk test; AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on 
Quality- of- Life Questionnaire; AFSS, Atrial Fibrillation Severity Scale; CPET, cardiopulmonary exercise testing; FCM, ferric 
carboxymaltose; Hb, haemoglobin; PGA, patient global assessment; QoL, quality- of- life; SF-36, 36- Item Short Form Survey; 
Tsat, transferrin saturation; TTE, transthoracic echocardiogram; VO2peak, peak oxygen uptake.
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and functional status. A patient global assessment score 
will be obtained from responses to the question ‘How do 
you feel about your life at the present time?’, given as a 
Box 1 Inclusion and exclusion criteria for the IRON- AF 
(Effect of Iron Repletion in Atrial Fibrillation) trial
Inclusion criteria
 ► At least 18 years of age
 ► Paroxysmal or persistent AF
 ► Stable medical therapy in the 4 weeks prior to enrolment with no 
dose changes of AF drugs in the last 2 weeks
 ► Haemoglobin <150 g/L
 ► Serum ferritin <100 µg/L or serum ferritin <300 µg/L if Tsat <20%
Exclusion criteria
 ► Known, or detected on screening, deficiency of vitamin B12 or se-
rum folate
 ► Known hypersensitivity to parenteral iron preparations
 ► History of primary or secondary haemochromatosis
 ► Known haemoglobinopathy or haemolytic anaemia
 ► History of erythropoietin- stimulating agent, intravenous iron therapy 
and/or blood transfusion in the 6 weeks prior to randomisation
 ► Requiring treatment with blood transfusion in the next 3 months
 ► Requiring surgery with anticipated moderate or severe blood loss in 
the next 3 months
 ► Ongoing blood loss
 ► Oral iron therapy at doses >80 mg/day (of elemental iron) in the 1 
week prior to randomisation (ongoing use of multivitamins contain-
ing ≤80 mg/day is permitted)
 ► Cardioversion, catheter ablation, AV nodal ablation with pacemaker 
insertion or surgical ablation within the past 3 months, or planned 
within the next 3 months
 ► Body weight ≤35 kg
 ► Exercise training programme(s) in the 3 months prior to screening, 
or planned in the next 3 months
 ► Current active autoimmune or systemic inflammatory diseases, or 
systemic infection or bacteraemia
 ► Screening AST/ALT above three times the upper limit of normal 
range
 ► Known chronic liver disease, hepatitis B or hepatitis C infection
 ► Known active malignancy, with the exception of squamous cell 
and basal cell carcinoma of the skin, and cervical intraepithelial 
neoplasia
 ► Currently receiving systemic chemotherapy and/or radiotherapy
 ► Known chronic kidney disease or history of dialysis, current dialysis 
or dialysis planned within the next 3 months
 ► Currently pregnant, breast feeding or trying to conceive within the 
next 3 months
 ► Acute myocardial infarction, transient ischaemic attack, or stroke 
within the last 3 months prior to randomisation
 ► Coronary artery bypass graft, percutaneous intervention or major 
surgery (including thoracic and cardiac surgery) within the last 3 
months (diagnostic catheterisations are allowed)
 ► Subject is unable to perform exercise testing, either because of 
investigator judgement or due to comorbidities severely impacting 
exercise capacity (including, but not limited to: severe valvular dis-
ease, severe obstructive lung disease, unstable angina)
 ► Subject is currently enrolled in, or is within 30 days of completion of, 
another interventional study
 ► Subject has previously been randomised to this study (subjects may 
be rescreened if they previously did not meet the eligibility criteria)
 ► Subject will not be available for completion of all assessments as 
per the study protocol
AF, atrial fibrillation; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; AV, atrioventricular; Tsat, transferrin saturation.
Figure 2 Ganzoni formula, used to calculate the repletion 
dosage of ferric carboxymaltose in the IRON- AF (Effect of 
Iron Repletion in Atrial Fibrillation) trial. BMI, body mass 
index; Hb, haemoglobin; IBW, ideal body weight.
Box 2 Primary, secondary and safety endpoints of the 
IRON- AF (Effect of Iron Repletion in Atrial Fibrillation) trial
Primary endpoints
 ► Change in VO2peak (mL/min/kg) from baseline to week 12
Secondary endpoints
 ► Change in SF-36 subscale scores from baseline to weeks 4, 8 and 
12
 ► Change in AFEQT overall and subset scores from baseline to weeks 
4, 8 and 12
 ► Change in AFSS severity and burden scores from baseline to weeks 
4, 8 and 12
 ► Change in PGA score from baseline to weeks 4, 8 and 12
 ► Change in fatigue score from baseline to weeks 4, 8 and 12
 ► Change in NYHA classification from baseline to weeks 4, 8 and 12
 ► Changes in laboratory parameters (including Hb, serum ferritin, iron, 
Tsat, NT- proBNP, CRP and ESR) from baseline to weeks 4, 8 and 12
 ► Changes in other CPET parameters (including ventilatory efficiency, 
VO2 at AT, HR at peak and AT, and peak oxygen pulse) from baseline 
to week 12
 ► Changes in TTE parameters (including left atrial and ventricular 
dimensions and volumes, diastolic function and ejection fractions) 
from baseline to week 12
 ► Change in 6MWT distance from baseline to week 12
 ► Change in 7- day Holter monitor- measured AF burden from baseline 
to week 12
 ► Hospitalisations (total, cardiovascular, heart failure, AF)
 ► Mortality (total, cardiovascular, AF)
Safety endpoints
 ► Hospitalisations and deaths
 ► Episodes of chest pain or hypotension during CPET
 ► Anaphylaxis or episodes of hypotension during or at completion of 
treatment infusion
 ► Episodes of serum ferritin >1000 µg/L
 ► Episodes of haemoglobin <70 g/L
 ► Episodes of elevated ALT, AST, urea and creatinine
6MWT, 6- minute walk test; AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect 
on Quality- of- Life Questionnaire; AFSS, Atrial Fibrillation Severity Scale; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; AT, anaerobic 
threshold; CPET, cardiopulmonary exercise testing; CRP, C- reactive protein; 
ESR, erythrocyte sedimentation rate; Hb, haemoglobin; HR, heart rate; NT- 
proBNP, NT- proB- type natriuretic peptide; NYHA, New York Heart Association; 
PGA, patient global assessment; SF-36, 36- Item Short Form Survey; Tsat, 
transferrin saturation; TTE, transthoracic echocardiogram; VO2, oxygen 
consumption; VO2peak, peak oxygen uptake.
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scale of 1 (‘worst possible life’) to 10 (‘best possible life’). 
This question is present on the AFSS but is not included 
in the calculation of the AFSS severity and burden scores. 
A fatigue score will also be included, given as a 10- point 
numeric rating scale ranging from 1 (‘no fatigue at all’) 
to 10 (‘very severe fatigue’). These questionnaires will 
be given to patients at baseline, weeks 4, 8 and 12, and 
summary scores will be calculated in accordance with 
established scoring criteria.
The 6MWT will be performed at baseline and week 12 
in accordance with a standardised protocol, in an area 
equipped with cardiopulmonary resuscitation facilities. 
Tests will be performed along a flat, straight route with 
a hard surface 32 m in length. Subjects will be instructed 
to walk the length of the course at their own pace and 
informed that the test will conclude after 6 min or if 
participants stopped, whichever occurs first. Coordina-
tors will give verbal encouragements and call out the time 
every minute. The total distance achieved during the test, 
to the nearest metre, will be recorded.
Seven- day Holter/Event monitors (Spiderflash, Micro-
port CRM, France) will be fitted onto participants at base-
line and week 12, and participants will be instructed on 
their use. In accordance with device capabilities, a contin-
uous Holter ECG will be recorded during the first 25 
hours, before the monitor switches to its event monitor 
function, where only periods of R- R instability ≥30 s will 
be recorded. AF burden will be defined as the percentage 
of time spent in AF during the 7- day monitoring period.
Hospitalisation and mortality information will be 
obtained from medical records. Events will be adjudi-
cated by a cardiologist blinded to the randomisation and 
categorised as cardiovascular (heart failure, AF, or other), 
non- cardiovascular, or of unknown cause.
Statistical analysis
Data analysis for efficacy will be performed according 
to the intention- to- treat principle for the assigned study 
groups. It is anticipated that randomisation of 70 patients 
will provide robust statistical power to detect plausible and 
clinically relevant improvement in VO2peak of 2 mL/min/
kg with a standard deviation of 3 mL/min/kg assuming 
80% power and two- sided alpha level of 0.05. This calcula-
tion is based on a prior randomised study in heart failure 
patients suggesting that iron deficient and replete indi-
viduals exhibit at least a clinically relevant 2 mL/min/
kg difference in VO2peak.
37 To allow for a 15% discontin-
uation rate, 84 patients will be recruited, equating to 42 
patients per group.
Continuous variables will be reported as mean and 
standard deviation, or median and interquartile range 
as appropriate. Categorical variables will be reported as 
number and percentage. The data will be checked for 
normality prior to the main analysis. Unpaired t- tests 
or Mann- Whitney U tests will be used to compare the 
changes in VO2peak between the two treatment arms, 
depending on the distribution of the data. Paired t- tests 
or Wilcoxon signed- rank tests will be used to evaluate the 
changes from baseline to week 12 in both treatment arms. 
All statistical tests will be two- sided, and a p value of <0.05 
will be considered significant. All analyses will be under-
taken using R V.4.0.2.
Ethics and dissemination
Ethics and governance approvals were obtained by the 
local Ethics Committee (Central Adelaide Local Health 
Network Committee, Australia; with additional accep-
tance of this approval by the University of Adelaide 
Human Research Ethics Committee). Written informed 
consent will be obtained from all study participants 
prior any study- specific assessments. The findings from 
this study will be disseminated through publications in 
peer- reviewed journals and national and international 
conferences.
DISCUSSION
This is the first study to examine the use of FCM in 
patients with AF and ID. The increasing burden of AF 
on individuals and healthcare systems warrants investiga-
tion into therapies that will improve the disease through 
novel mechanisms. Knowledge on the epidemiology and 
pathophysiology of ID in AF is still emerging. An investi-
gation into the safety and efficacy of iron supplementa-
tion in these patients provides a logical starting point in 
this area. The results of this study will provide evidence 
on the importance of screening and correcting ID in 
patients with AF.
Iron repletion has an established role in HFrEF patients. 
The large, multinational FAIR- HF (Ferinject Assessment 
in Patients with Iron Deficiency and Chronic Heart 
Failure) and CONFIRM- HF (Ferric Carboxymaltose Eval-
uation on Performance in Patients with Iron Deficiency in 
Combination with Chronic Heart Failure) trials demon-
strated that iron repletion with intravenous FCM signifi-
cantly improves symptoms, exercise tolerance and QoL 
in these patients. Importantly in FAIR- HF, this was irre-
spective of the presence of anaemia. Societal guidelines 
have since recommended iron testing on initial diagnosis 
of heart failure, as well as treatment of comorbid ID.38 
Recently, the AFFIRM- AHF (A Randomised, Double- 
blind Placebo Controlled Trial Comparing the Effect of 
Intravenous Ferric Carboxymaltose on Hospitalisations 
and Mortality in Iron Deficient Subjects Admitted for 
Acute Heart Failure) trial also demonstrated reduction 
in the risk of heart failure hospitalisations following iron 
repletion in HFrEF patients.31
Improving the symptomatology of AF and QoL is an 
important, but oft- neglected aspect of care. ID may be 
a common comorbidity in these patients and correcting 
the deficiency in other patient populations has been 
shown to improve the symptoms of fatigue and exercise 
tolerance. Beyond its intrinsic appeal, improvements in 
these symptoms may lead to improved engagement in risk 
factor management in patients with AF. The IRON- AF 
study began recruitment in July 2020 following delays due 
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to the COVID-19 pandemic and is expected to complete 
recruitment by the end of 2021.
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